300006 莱美药业
已收盘 09-30 15:00:00
资讯
新帖
简况
莱美药业:9月23日召开业绩说明会,投资者参与
证券之星 · 09-23
莱美药业:9月23日召开业绩说明会,投资者参与
股市必读:莱美药业(300006)9月16日董秘有最新回复
证券之星 · 09-17
股市必读:莱美药业(300006)9月16日董秘有最新回复
莱美药业:截至2026年9月10日,公司股东户数为27,445
证券之星 · 09-16
莱美药业:截至2026年9月10日,公司股东户数为27,445
股市必读:莱美药业新发布《关于全资子公司获得化学原料药上市申请批准通知书的公告》
证券之星 · 09-15
股市必读:莱美药业新发布《关于全资子公司获得化学原料药上市申请批准通知书的公告》
莱美药业(300006.SZ)子公司非奈利酮原料药获批上市
智通财经 · 09-14
莱美药业(300006.SZ)子公司非奈利酮原料药获批上市
莱美药业(300006)8月20日股东户数2.36万户,较上期减少8.53%
证券之星 · 08-27
莱美药业(300006)8月20日股东户数2.36万户,较上期减少8.53%
莱美药业:截至2026年8月20日,公司股东户数为23,635
证券之星 · 08-27
莱美药业:截至2026年8月20日,公司股东户数为23,635
股市必读:莱美药业新发布《关于独立董事取得独立董事培训证明的公告》
证券之星 · 08-26
股市必读:莱美药业新发布《关于独立董事取得独立董事培训证明的公告》
图解莱美药业中报:第二季度单季净利润同比增长52.25%
证券之星 · 08-21
图解莱美药业中报:第二季度单季净利润同比增长52.25%
莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%
证券之星 · 08-20
莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%
Moderna癌症疫苗三期成功 创新药、疫苗板块大幅高开 莱美药业等一字涨停
中金财经 · 08-20
Moderna癌症疫苗三期成功 创新药、疫苗板块大幅高开 莱美药业等一字涨停
生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报
格隆汇 · 08-20
生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报
莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%
证券之星 · 08-10
莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%
莱美药业(300006.SZ)获得吸入用乙酰半胱氨酸溶液药品注册证书
智通财经 · 08-10
莱美药业(300006.SZ)获得吸入用乙酰半胱氨酸溶液药品注册证书
莱美药业:截至2026年7月31日,公司股东户数为25,384
证券之星 · 08-10
莱美药业:截至2026年7月31日,公司股东户数为25,384
莱美药业(300006)7月20日股东户数2.38万户,较上期减少2.57%
证券之星 · 07-27
莱美药业(300006)7月20日股东户数2.38万户,较上期减少2.57%
莱美药业(300006)披露签署《药品上市许可转让协议》公告,7月23日股价下跌4.55%
证券之星 · 07-23
莱美药业(300006)披露签署《药品上市许可转让协议》公告,7月23日股价下跌4.55%
莱美药业(300006.SZ)与天之海药业签署关于维生素D₂软胶囊药品上市许可转让协议
智通财经网 · 07-23
莱美药业(300006.SZ)与天之海药业签署关于维生素D₂软胶囊药品上市许可转让协议
股市必读:莱美药业(300006)股东户数2.45万户,较上期减少1.05%
证券之星 · 07-20
股市必读:莱美药业(300006)股东户数2.45万户,较上期减少1.05%
莱美药业(300006)7月10日股东户数2.45万户,较上期减少1.05%
证券之星 · 07-17
莱美药业(300006)7月10日股东户数2.45万户,较上期减少1.05%
加载更多
公司概况
公司名称:
重庆莱美药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-10-30
主营业务:
重庆莱美药业股份有限公司的主营业务是医药制造。公司的主要产品是特色专科类化药(包括抗肿瘤药、消化系统药、肠外营养药)、抗感染类化药。公司2019年被工信部认定为“国家技术创新示范企业”,荣获“新中国成立70年医药产业标杆企业”,2021年被重庆市经信委评为重庆市工业和信息化重点实验室,2022年被国家知识产权局评为“国家知识产权示范企业”,2024年被制造业跃升领导小组办公室评为“制造业跃升发展创新领军企业”,2025年被南岸区重庆经开区制造业高质量发展办公室评为“制造业创新领军企业”,2026年被全联药业商会评为2025-2026年度医药行业自主创新企业。
发行价格:
16.50
{"stockData":{"symbol":"300006","market":"SZ","secType":"STK","nameCN":"莱美药业","latestPrice":5.56,"timestamp":1790751834000,"preClose":5.3,"halted":0,"volume":34433879,"delay":0,"changeRate":0.0491,"floatShares":1056000000,"shares":1056000000,"eps":-0.1201,"marketStatus":"已收盘","change":0.26,"latestTime":"09-30 15:00:00","open":5.32,"high":5.62,"low":5.3,"amount":189000000,"amplitude":0.0604,"askPrice":5.56,"askSize":33,"bidPrice":5.55,"bidSize":1441,"shortable":0,"etf":0,"ttmEps":-0.1201,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":5.3,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":5.83,"lowLimit":4.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1055911205,"isCdr":false,"pbRate":3.23,"roa":"--","roe":"--","epsLYR":-0.1276,"committee":-0.143949,"marketValue":5871000000,"turnoverRate":0.0326,"status":0,"floatMarketCap":5870000000},"requestUrl":"/m/hq/s/300006","defaultTab":"news","newsList":[{"id":"2669748267","title":"莱美药业:9月23日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669748267","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669748267?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:01","pubTimestamp":1790175710,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月23日莱美药业发布公告称公司于2026年9月23日召开业绩说明会。关于产品研发进展情况公司将严格按照相关规定履行信息披露义务。目前子公司四川瀛瑞纳米炭铁混悬注射液联合放疗已正式进入二期临床阶段,四川瀛瑞正积极推进相关工作,确保试验的顺利进行。同时,持续深化经营管理,严格控制成本费用并严格控制销售费用率,提高公司盈利能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668987157","title":"股市必读:莱美药业(300006)9月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987157","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668987157?lang=zh_cn&edition=full","pubTime":"2026-09-17 01:00","pubTimestamp":1789578047,"startTime":"0","endTime":"0","summary":"截至2026年9月16日收盘,莱美药业报收于5.11元,上涨0.79%,换手率1.19%,成交量12.52万手,成交额6383.68万元。董秘最新回复投资者: 董秘您好!请问截止9月8号,公司的股东人数是多少?截至2026年9月10日,公司股东户数为27,445。当日关注点交易信息汇总:9月16日主力资金净流入63.23万元,占总成交额0.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700000569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667460955","title":"莱美药业:截至2026年9月10日,公司股东户数为27,445","url":"https://stock-news.laohu8.com/highlight/detail?id=2667460955","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667460955?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:51","pubTimestamp":1789548665,"startTime":"0","endTime":"0","summary":"证券之星消息,莱美药业(300006)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司截止9月10日最新股东户数是多少?谢谢莱美药业回复:尊敬的投资者,您好。截至2026年9月10日,公司股东户数为27,445。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660163","title":"股市必读:莱美药业新发布《关于全资子公司获得化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667660163?lang=zh_cn&edition=full","pubTime":"2026-09-15 01:02","pubTimestamp":1789405344,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘,莱美药业报收于5.16元,上涨0.78%,换手率1.84%,成交量19.42万手,成交额1.0亿元。公司公告汇总:全资子公司获国家药监局签发非奈利酮《化学原料药上市申请批准通知书》,该原料药用于治疗与2型糖尿病相关的慢性肾病成人患者。截至目前,国内已有包括莱美隆宇在内的14家企业获批非奈利酮原料药上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500000599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667327659","title":"莱美药业(300006.SZ)子公司非奈利酮原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667327659","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667327659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:14","pubTimestamp":1789373691,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱美药业(300006.SZ)发布公告,近日,公司全资子公司重庆莱美隆宇药业有限公司(简称莱美隆宇)收到国家药品监督管理局核准签发的非奈利酮《化学原料药上市申请批准通知书》。非奈利酮是一种非甾体选择性盐皮质激素受体(MR)拮抗剂,其制剂用于治疗与2型糖尿病相关的慢性肾病成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0070","BK0239","300006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662031977","title":"莱美药业(300006)8月20日股东户数2.36万户,较上期减少8.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662031977","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662031977?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:12","pubTimestamp":1787825526,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱美药业披露,截至2026年8月20日公司股东户数为2.36万户,较8月10日减少2204.0户,减幅为8.53%。在化学制药行业个股中,莱美药业股东户数低于行业平均水平,截至8月20日,化学制药行业平均股东户数为3.67万户。从股价来看,2026年8月10日至2026年8月20日,莱美药业区间涨幅为11.03%,在此期间股东户数减少2204.0户,减幅为8.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662265377","title":"莱美药业:截至2026年8月20日,公司股东户数为23,635","url":"https://stock-news.laohu8.com/highlight/detail?id=2662265377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662265377?lang=zh_cn&edition=full","pubTime":"2026-08-27 08:36","pubTimestamp":1787790976,"startTime":"0","endTime":"0","summary":"证券之星消息,莱美药业(300006)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问:请问8月20日股东人数是多少?谢谢莱美药业回复:尊敬的投资者,您好。截至2026年8月20日,公司股东户数为23,635。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700016349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760768","title":"股市必读:莱美药业新发布《关于独立董事取得独立董事培训证明的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760768","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760768?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:35","pubTimestamp":1787700914,"startTime":"0","endTime":"0","summary":"公司公告汇总关于独立董事取得独立董事培训证明的公告重庆莱美药业股份有限公司第六届董事会独立董事杜娟娟女士,已参加深圳证券交易所举办的上市公司独立董事任前培训,并取得深圳证券交易所创业企业培训中心颁发的《上市公司独立董事培训证明》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600012580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661398932","title":"图解莱美药业中报:第二季度单季净利润同比增长52.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661398932","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661398932?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:15","pubTimestamp":1787246110,"startTime":"0","endTime":"0","summary":"证券之星消息,莱美药业2026年中报显示,上半年度公司主营收入3.5亿元,同比下降7.09%;归母净利润-2341.75万元,同比上升25.37%;扣非净利润-2577.49万元,同比上升20.04%;其中2026年第二季度,公司单季度主营收入1.68亿元,同比下降5.91%;单季度归母净利润-840.48万元,同比上升52.25%;单季度扣非净利润-1030.46万元,同比上升42.57%;负债率35.96%,投资收益-1856.66万元,财务费用-411.48万元,毛利率51.9%。财报数据概要请见下图:本文数据来源于莱美药业2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660888632","title":"莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660888632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660888632?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:37","pubTimestamp":1787218662,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱美药业披露,截至2026年7月31日公司股东户数为2.54万户,较7月20日增加1542.0户,增幅为6.47%。在化学制药行业个股中,莱美药业股东户数低于行业平均水平,截至7月31日,化学制药行业平均股东户数为3.7万户。从股价来看,2026年7月20日至2026年7月31日,莱美药业区间涨幅为6.1%,在此期间股东户数增加1542.0户,增幅为6.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660778834","title":"Moderna癌症疫苗三期成功 创新药、疫苗板块大幅高开 莱美药业等一字涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2660778834","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660778834?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:04","pubTimestamp":1787191443,"startTime":"0","endTime":"0","summary":"Moderna癌症疫苗三期成功 创新药、疫苗板块大幅高开 莱美药业等一字涨停 分时图\r\n\r\n 8月20日消息,早盘创新药、疫苗板块大幅高开,莱美药业、沃森生物、康希诺、键凯科技、悦康药业、双鹭药业、百克生物等一字涨停,智飞生物、石药创新、康泰生物等涨超10%。\r\n\r\n 消息面上,隔夜美股莫德纳股价大涨近180%。默沙东与莫德纳周三宣布,双方合作的 mRNA 个性化癌症疫苗 intismeran autogene 首个 III 期临床试验取得初步阳性结果。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/20/20260820203988.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/20/20260820203988.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260820/32340703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK1161","06978","159992","MEDX","LNGR","BK1574","IBBQ","BK0070","300006","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727484","title":"生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727484","media":"格隆汇","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727484?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:47","pubTimestamp":1787190439,"startTime":"0","endTime":"0","summary":"8月20日,A股市场生物疫苗股全线大涨,其中,百克生物、康希诺、沃森生物、莱美药业、智飞生物20CM涨停,康华生物逼近20CM涨停,康泰生物涨超17%,华兰疫苗涨超10%,德展健康、双鹭药业、海普瑞、海欣股份、万泰生物10CM涨停,金迪克、博晖创新涨超7%,西藏药业、卫光生物、利德曼、冠昊生物、塞力医疗、赛升药业、申联生物、欧林生物涨超6%。消息面上,默沙东与莫德纳周三宣布,联合研发的黑色素瘤皮肤癌疫苗在首次晚期临床试验中取得积极初步结果。\n\n港股频道更多独家策划、专家专栏,免费查阅>>\n\n 责任编辑:栎树","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20094758182842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B1BXHZ80.USD","LU1069347547.HKD","LU0098860793.USD","LU0234572021.USD","LU2468319806.SGD","LU2112291526.USD","LU1328615791.USD","301207","300142","LU0965509101.SGD","LU2357627491.SGD","LU0965509283.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","PAWZ","LU0130517989.USD","IE0009355771.USD","LU1116320737.USD","LU1037948541.HKD","LU0320765489.SGD","BK0077","LU0124676726.USD","IE00BSNM7G36.USD","LU0203345920.USD","BK0188","LU1037948897.HKD","LU0477156953.USD","LU1116320901.HKD","300006","LU1066051498.USD","SG9999015341.SGD","MRNX","LU0006306889.USD","JDOC","LU0965509010.AUD","LU1162221912.USD","LU1974910355.USD","BK4532","IE00BBT3K403.USD","SG9999002224.SGD","LU1093756325.SGD","LU0265550359.USD","SG9999001440.SGD","BK0046","LU0868494708.USD","LU0648001328.SGD","LU2580892862.HKD","LU2491049909.HKD","LU1983299246.USD","MRK","IE000M9KFDE8.USD","LU1585245621.USD","RXL","LU1035773651.USD","LU1430594728.SGD","300122","LU1571399168.USD","LU1699723380.USD","LU2433249047.HKD","LU2148510915.USD","LU1989771016.USD","LU1989772923.USD","LU0823416689.USD","IE00B2B36J28.USD","BK4568","IE00B4R5TH58.HKD","LU2361045086.USD","SG9999014559.SGD","IYH","SGXZ57979304.SGD","BK0070","LU2106854487.HKD","MRNA","LU2023250504.SGD","LU0122379950.USD","LU0861579265.USD","BK4534","LU0106261372.USD","LU0289739699.SGD","06185","WDNA","IHE","LU1066051225.USD","XLV","SG9999001176.SGD","TRUH","HRTS","IDNA","LU1934455194.USD","VHT","IE00BLSP4452.SGD","BK4550","LU1291159041.SGD","IE00BLSP4239.USD","LU1023059063.AUD","BK4585","BK4139","LU2360032135.SGD","LU1064130708.USD","LU1923622614.USD","688185","SG9999014542.SGD","LU1064131003.USD","LU1057294990.SGD","PPH","LU1093756168.USD","IE0002141913.USD","LU0203347892.USD","BK0196","LU2491050154.USD","LU2361044949.HKD","LU1061106388.HKD","LU1941712348.USD","BK4533","LU1934455277.USD","BK4548","BK0239","LGHT","LU0432979614.USD","LU0965508806.USD","LU2580892789.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","SG9999013999.USD","LU0868494617.USD","LU0238689110.USD","LU0058720904.USD","LU0942090050.USD","BK4501","LU0130102774.USD","MRNY","LU0208291251.USD","GDOC","IE00BFTCPJ56.SGD","LU1934455863.HKD","LU1917777945.USD","SG9999001176.USD","LU1989772840.SGD","LU0266013472.USD","BK4516","LU2125909593.SGD","FTXH","LU2361044865.SGD","GNOM","LU0689626769.HKD","SG9999015358.SGD","LU2125154935.USD","LU0985320562.USD","IXJ","LU2125154778.USD","BK4007","LU0320765646.SGD","LU1941712264.USD","LU0265550946.USD","LU2023250843.SGD","SG9999014567.USD","BK4559","SG9999014575.USD","LU1201861249.SGD","LU2491050071.SGD","SG9999002232.USD","BK4551","LU0070302665.USD","BK4588","LU0980610538.SGD","LU2089984988.USD","LU2461242641.AUD","IE00BN8TJ469.HKD","LU2324357040.USD","LU0859254822.USD","LU1929549753.HKD","LU2125909247.SGD","LU1066051811.HKD","FHLC","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658984704","title":"莱美药业(300006)7月31日股东户数2.54万户,较上期增加6.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658984704","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658984704?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:36","pubTimestamp":1786354577,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱美药业披露,截至2026年7月31日公司股东户数为2.54万户,较7月20日增加1542.0户,增幅为6.47%。在化学制药行业个股中,莱美药业股东户数低于行业平均水平,截至7月31日,化学制药行业平均股东户数为3.59万户。从股价来看,2026年7月20日至2026年7月31日,莱美药业区间涨幅为6.1%,在此期间股东户数增加1542.0户,增幅为6.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000022704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986447","title":"莱美药业(300006.SZ)获得吸入用乙酰半胱氨酸溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986447","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986447?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:56","pubTimestamp":1786348591,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱美药业(300006.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的吸入用乙酰半胱氨酸溶液(3ml:0.3g)《药品注册证书》。本次获得吸入用乙酰半胱氨酸溶液的《药品注册证书》,将有利于进一步丰富公司产品线,提升公司竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"莱美药业(300006.SZ)获得吸入用乙酰半胱氨酸溶液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658865879","title":"莱美药业:截至2026年7月31日,公司股东户数为25,384","url":"https://stock-news.laohu8.com/highlight/detail?id=2658865879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658865879?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:39","pubTimestamp":1786347554,"startTime":"0","endTime":"0","summary":"证券之星消息,莱美药业(300006)08月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止到7月31日公司股东人数是多少?谢谢莱美药业回复:尊敬的投资者,您好。截至2026年7月31日,公司股东户数为25,384。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000014583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654165260","title":"莱美药业(300006)7月20日股东户数2.38万户,较上期减少2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654165260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654165260?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:35","pubTimestamp":1785144959,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱美药业披露,截至2026年7月20日公司股东户数为2.38万户,较7月10日减少629.0户,减幅为2.57%。在化学制药行业个股中,莱美药业股东户数低于行业平均水平,截至7月20日,化学制药行业平均股东户数为3.58万户。从股价来看,2026年7月10日至2026年7月20日,莱美药业区间跌幅为5.36%,在此期间股东户数减少629.0户,减幅为2.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700022889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653872982","title":"莱美药业(300006)披露签署《药品上市许可转让协议》公告,7月23日股价下跌4.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653872982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653872982?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:33","pubTimestamp":1784817195,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘,莱美药业报收于5.03元,较前一交易日下跌4.55%,最新总市值为53.11亿元。近日,重庆莱美药业股份有限公司与江西天之海药业股份有限公司签署《药品上市许可转让协议》,以2800万元受让维生素D软胶囊的药品注册批文及全球范围内的全部商业和市场权益。本次交易不构成关联交易或重大资产重组,无需提交董事会及股东会审议。过渡期内,莱美药业可委托天之海药业生产。药品上市许可持有人变更需经国家药监局审批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653748636","title":"莱美药业(300006.SZ)与天之海药业签署关于维生素D₂软胶囊药品上市许可转让协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2653748636","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653748636?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:56","pubTimestamp":1784797003,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱美药业 发布公告,公司与江西天之海药业股份有限公司于近期签署了《药品上市许可转让协议》。根据该协议,公司以人民币2800万元受让天之海药业持有的维生素D软胶囊的药品注册批文、全球范围内现有的全部商业和市场权益及协议产品涉及的其他全部权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300006","BK0239","IPOS","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652257275","title":"股市必读:莱美药业(300006)股东户数2.45万户,较上期减少1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652257275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652257275?lang=zh_cn&edition=full","pubTime":"2026-07-20 03:02","pubTimestamp":1784487738,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,莱美药业报收于4.56元,下跌8.98%,换手率3.37%,成交量35.54万手,成交额1.68亿元。股本股东变化:截至2026年7月10日,莱美药业股东户数为2.45万户,较6月30日减少259.0户,减幅1.05%。交易信息汇总资金流向7月17日主力资金净流入16.7万元;游资资金净流入1149.72万元,占总成交额0.0%;散户资金净流出1166.42万元,占总成交额0.0%。户均持股数量由上期的4.27万股增加至4.31万股,户均持股市值为20.93万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000001438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404882","title":"莱美药业(300006)7月10日股东户数2.45万户,较上期减少1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404882","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652404882?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:48","pubTimestamp":1784281725,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱美药业披露,截至2026年7月10日公司股东户数为2.45万户,较6月30日减少259.0户,减幅为1.05%。在化学制药行业个股中,莱美药业股东户数低于行业平均水平,截至7月10日,化学制药行业平均股东户数为3.56万户。从股价来看,2026年6月30日至2026年7月10日,莱美药业区间跌幅为5.46%,在此期间股东户数减少259.0户,减幅为1.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700032904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791097348060,"stockEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0263},{"period":"3month","weight":0.1187},{"period":"6month","weight":-0.1472},{"period":"1year","weight":0.2991},{"period":"ytd","weight":0.0817}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆莱美药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27445人(较上一季度减少5.26%)","perCapita":"38470股","listingDate":"2009-10-30","address":"重庆市南岸区玉马路99号","registeredCapital":"105591万元","survey":" 重庆莱美药业股份有限公司的主营业务是医药制造。公司的主要产品是特色专科类化药(包括抗肿瘤药、消化系统药、肠外营养药)、抗感染类化药。公司2019年被工信部认定为“国家技术创新示范企业”,荣获“新中国成立70年医药产业标杆企业”,2021年被重庆市经信委评为重庆市工业和信息化重点实验室,2022年被国家知识产权局评为“国家知识产权示范企业”,2024年被制造业跃升领导小组办公室评为“制造业跃升发展创新领军企业”,2025年被南岸区重庆经开区制造业高质量发展办公室评为“制造业创新领军企业”,2026年被全联药业商会评为2025-2026年度医药行业自主创新企业。","listedPrice":16.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱美药业,300006,莱美药业股票,莱美药业股票老虎,莱美药业股票老虎国际,莱美药业行情,莱美药业股票行情,莱美药业股价,莱美药业股市,莱美药业股票价格,莱美药业股票交易,莱美药业股票购买,莱美药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}